Sirona Biochem Corp V.SBM

Alternate Symbol(s): SRBCF

Healthcare Biotechnology

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.

TSXV:SBM - Post by User

Sirona Biochem Corp

Bullboard Posts

Comment by Pareto8020on Nov 12, 2020 5:59am

151 Views

Post# 31883419

RE:RE:Silence

Considering this statement from their manufacturing news release in September....

Sirona anticipates the need for multi-kilogram production of TFC-1067 through the remainder of 2020 with sustained large-scale quantities for commercialization required in 2021.

You would think by now it would be apparent or officially announced who is using or consuming all these needed multi-kilo's of their product and better yet how much they are paying for it. SBM needs to announce something major by year end which is only a month and a half away otherwise we should flood Howie's / SBM mailbox with requests for a new CEO. He's the Barney Fife of CEO's when SBM needs a Gordon Gekko.

Bullboard Posts

Rig Count Soars as Utilization Surpasses Industry Averages